SOUTH SAN FRANCISCO, Calif., Feb. 19 /PRNewswire-FirstCall/ -- Exelixis, Inc. (Nasdaq: EXEL) announced today that Michael Morrissey, Ph.D., senior vice president of discovery research will present at the 6th Annual BIO CEO & Investor Conference.

Dr. Morrissey will present a general company presentation at 2:30pm ET on Wednesday, February 25th, 2004. He will also participate in a focus session on February 25th at 9:30am ET entitled, Pathways Based Drug Discovery: Using Pathway Intersections to Optimize Drug Intervention and second focus session on February 25th at 3:30pm ET entitled, Drug Discovery: Engines That Build Pipelines.

The presentation and focus sessions will be webcast and may be accessed in the Events page under Investor Information on the Exelixis website at http://www.exelixis.com/index.asp?secPage=events.

About Exelixis, Inc.

Exelixis, Inc. is a leading genomics-based drug discovery company dedicated to the discovery and development of novel therapeutics. The company is leveraging its fully integrated gene-to-drug platform to fuel the growth of its proprietary drug pipeline. Exelixis' development pipeline includes: XL119, which is anticipated to enter a Phase 3 clinical trial as a potential treatment for bile duct tumors; XL784, an anticancer compound that has completed a Phase 1 clinical trial; XL647, XL999 and XL844, anticancer compounds that are potential IND candidates; and multiple compounds in preclinical development. Exelixis has established broad corporate alliances with major pharmaceutical and biotechnology companies, including GlaxoSmithKline and Bristol-Myers Squibb Company. After completion of Phase 2a clinical trials, GlaxoSmithKline has the right to elect to develop a certain number of the cancer compounds identified in this release, other than XL119, thus potentially triggering milestone payments and royalties from GlaxoSmithKline and co-promotion by Exelixis. The company has also established agricultural research collaborations with Bayer CropScience, Dow AgroSciences and Renessen LLC. Other partners include Merck & Co., Inc., Schering-Plough Research Institute, Inc., Cytokinetics, Inc., Elan Pharmaceuticals, Inc. and Scios Inc. For more information, please visit the company's web site at www.exelixis.com.

SOURCE  Exelixis, Inc.
    -0-                             02/19/2004
    /CONTACT:  Jane M. Green, Ph.D., VP, Corporate Communications, of
Exelixis, Inc., +1-650-837-7579 or jmgreen@exelixis.com/
    /Web site:  http://www.exelixis.com /
    (EXEL)

CO:  Exelixis, Inc.
ST:  California, New York
IN:  HEA BIO
SU:  TDS CCA

JO 
-- SFTH074 --
3980 02/19/2004 16:00 EST http://www.prnewswire.com